C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/13 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) C07K 16/28 (2006.01) C07K 16/30 (2006.01) C12N 5/12 (2006.01) C12N 15/63 (2006.01)
Patent
CA 2546763
The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non- ~cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
L'invention concerne des procédés et des compositions conçus pour le traitement, la maîtrise, ou la prévention du cancer, notamment le cancer métastatique. Les procédés consistent à administrer une quantité efficace d'un ou plusieurs anticorps qui se lient à l'activité d'EphA2 et qui la renforcent, augmentant ainsi la phosphorylation de l'EphA2 et de faire baisser les niveaux d'EphA2 dans les cellules dans lesquelles l'activité d'EphA2 a été renforcée. L'invention concerne aussi des anticorps qui se lient de préférence à un épitope d'EphA2 exposé sur des cellules cancéreuses et non sur des cellules non cancéreuses, et des compositions pharmaceutiques contenant une ou plusieurs anticorps d'EphA2 de l'invention soit seuls, soit en combinaison avec un ou plusieurs autres agents utiles dans le traitement du cancer.
Carles-Kinch Kelly
Kinch Michael S.
Stewart Jane C.
Medimmune Inc.
Osler Hoskin & Harcourt Llp
Purdue Research Foundation
LandOfFree
Epha2 agonistic monoclonal antibodies and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Epha2 agonistic monoclonal antibodies and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epha2 agonistic monoclonal antibodies and methods of use... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1546264